Low
₹758.50
High
₹781.90
| Previous Close | ₹764.20 |
|---|---|
| Day's Range | ₹758.50 - ₹781.90 |
| Open | ₹774.50 |
| 52 Week Range | ₹432.60 - ₹804.30 |
| Volume | 5,55,260 |
| Market Cap | ₹0.02 |
| Trade Value ( ₹ in Lacs) | 4,259.40 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.23 |
| Price/Earning (TTM) | 31.80 |
| TTM EPS (₹) | 24.01 |
| P/E Ratio | 23.56 |
| Book Value(₹) | 3.72 |
| PAT Margin (%) | 6.73 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 16.16 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 30301.63 | 7680.26 |
| Expenses | N/A | N/A |
| PBT | 4272.24 | 1266.9 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 3193.36 | 940.54 |
| Founded | 1991 |
|---|---|
| Managing Director | Krishna Prasad Chigurupati |
| NSE Symbol | GRANULES |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,792.16 | 1,861.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,151.98 | 6,705.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,914.73 | 4,524.00 | 3,171.90 - 3,171.90 |
| Apollo Hospitals Enterprise Ltd. | 1,23,557.75 | 8,589.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,353.96 | 1,439.95 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,12,681.23 | 1,351.00 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,09,875.05 | 1,100.70 | 835.50 - 835.50 |
| Max Healthcare Institute Ltd. | 1,09,280.68 | 1,122.85 | 903.00 - 903.00 |
| Lupin Ltd. | 1,07,090.72 | 2,346.00 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,01,632.12 | 2,462.80 | 1,909.70 - 1,909.70 |
No Records Found
Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Granules Code of Conduct for Prevention of Insider Trading, Granules India has informed that the Trading Window for dealing in the securities of the Company shall remain closed for all Insiders including the Designated Persons and their immediate relatives from July 01, 2026 till 48 hours after the declaration of the un-audited financial results for the first quarter of FY 27 ending on June 30, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Granules India Ltd. is ₹764.20 as of 2026-06-25.
The market capitalisation of Granules India Ltd. is ₹18,920.53 as of 2026-06-25.
The 1-year return of Granules India Ltd. is 267.00% as of 2026-06-25.
The P/E ratio of Granules India Ltd. is 23.56 as of 2026-06-28.
The 52-week high and low of Granules India Ltd. are ₹804.30 and ₹432.60, respectively, as of 2026-06-25.
Granules India Ltd. engages with global pharmaceutical companies through contract manufacturing and long-term supply arrangements. The company supplies pharmaceutical ingredients and formulations at scale, supporting partners in their manufacturing and supply chain requirements.
Granules India Ltd. focuses on high-volume pharmaceutical products, including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Its portfolio includes widely used drugs such as paracetamol and ibuprofen.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.